Pulmonary Involvement In Pediatric Malignancies

← Back to Index(🩸 Hematology and Oncology)

Primary Lung Tumors And Genetic Associations

Epithelial tumors (adenocarcinomas) of the lung characterize adult malignancies but remain exceptionally rare in children.

Pleuropulmonary Blastoma: Strongly associated with DICER1 mutations. Familial pleuropulmonary blastoma predisposition syndrome significantly increases risk.
Primary Lung Cancer: Rare occurrences may harbor EGFR (7p) amplifications (tyrosine kinase growth factor receptors).

Metastatic Pulmonary Disease

Lungs constitute the primary metastatic destination for numerous pediatric solid tumors. Identification mandates high-resolution chest computed tomography (CT).

Solid Tumor Metastatic Profiles

Primary Malignancy	Pulmonary Metastasis Characteristics	Therapeutic Approach
Wilms Tumor	Defines Stage IV disease. Detected via CT.	Regimen DD4A or M. Rapid response eliminates radiation need. Whole-lung radiation utilized for incomplete response at 6 weeks.
Osteosarcoma	Early, frequent hematogenous spread to lungs.	Complete surgical resection of primary tumor and pulmonary metastasectomy. Chemotherapy essential. Addition of muramyl-tripeptide phosphatidylethanolamine (MTP-PE) improves survival.
Ewing Sarcoma	High metastatic predilection for lungs.	Intensive systemic chemotherapy. Whole-lung radiation (12-21 Gy) standard for pulmonary involvement.
Rhabdomyosarcoma	Predominantly occurs with alveolar subtype and extremity primaries. Widespread dissemination portends poor prognosis.	Multi-agent chemotherapy (Vincristine, Actinomycin D, Cyclophosphamide). Lung metastases render disease high-risk (except embryonal RMS <10 years with isolated lung lesions).
Hepatoblastoma / Hepatocellular Carcinoma	Present in 10-20% of patients at diagnosis.	Preresection chemotherapy. Complete regression achievable with chemotherapy and surgical resection of isolated pulmonary metastases (25% survival).
Clear Cell Sarcoma Of Kidney	High propensity for lung, bone, and brain metastasis.	Nephrectomy, radiation, and intensive chemotherapy (cyclophosphamide, etoposide, vincristine, doxorubicin).
Extracranial Germ Cell Tumors	Choriocarcinoma variant (infantile) manifests with frequent pulmonary disease. Presents with hemoptysis secondary to hemorrhage.	Platinum-based chemotherapy (Bleomycin, Etoposide, Cisplatin).

Hematologic Malignancies Involving Lungs And Thorax

Leukemias and lymphomas frequently compromise the respiratory system via direct infiltration, nodal mass effect, or leukostasis.

Leukemic Pulmonary Infiltration

Infant Acute Lymphoblastic Leukemia (ALL): Presents frequently with diffuse pulmonary infiltration by leukemic cells causing severe tachypnea.
Hyperleukocytosis/Leukostasis: White blood cell count >100,000/mm³. Causes noncardiogenic pulmonary edema, hypoxemia, and dyspnea secondary to microvascular sludging and hemorrhage.
Radiologic Findings: Diffuse interstitial or alveolar infiltrates on chest radiograph; hemorrhage or leukemic infiltrates visible on CT.

Lymphoma And Anterior Mediastinal Masses

Etiology: T-cell ALL, T-lymphoblastic lymphoma (LL), Primary Mediastinal B-cell Lymphoma (PMBL), and Hodgkin Lymphoma.
Clinical Presentation: 25% of NHL patients exhibit anterior mediastinal masses. Presents with cough, wheezing, orthopnea, stridor, and dyspnea.
Pleural Effusions: Common thoracic complication restricting cardiopulmonary function.
Stage IV Hodgkin Lymphoma: Defined by extralymphatic spread including lung parenchyma.

Langerhans Cell Histiocytosis (Pulmonary Manifestations)

Multisystem Langerhans Cell Histiocytosis (LCH) involves the lungs in 15% of cases.

Clinical Signs: Dyspnea, dry cough, tachypnea, pneumothorax.
Imaging: High-resolution CT reveals diffuse lung cysts with parenchymal destruction, generating a characteristic "honeycomb" appearance.
Prognostic Note: Lung involvement is no longer universally categorized as a high-risk mortality organ, but still requires comprehensive systemic evaluation.

Pulmonary Oncologic Emergencies

Thoracic masses present immediate, life-threatening airway and vascular compromise requiring urgent intervention.

Superior Vena Cava / Superior Mediastinal Syndrome

Pathophysiology: Malignant anterior mediastinal tumors compressing trachea, bronchi, and superior vena cava.
Symptomatology: Supine positioning worsens dyspnea. Facial edema, plethora, cyanosis, distended neck veins, syncope.
Anesthetic Risk: Extreme risk of cardiopulmonary arrest upon flat positioning or general anesthesia.
Management: Airway imaging (CT with airway measurements) mandatory. Utilize least invasive biopsy possible (peripheral node under local anesthesia). Administer preoperative corticosteroids (dexamethasone) for up to 48 hours to relieve critical airway narrowing prior to definitive diagnosis.

Multimodal therapy introduces significant risk for acute pneumonitis and chronic restrictive lung disease. Children <3 years exhibit highest vulnerability.

Therapy-Induced Lung Injury

Modality / Agent	Pulmonary Complications	Associated Risk Factors
Bleomycin	Pulmonary fibrosis. Decreased diffusion capacity (DLCO).	Cumulative dose >200-400 units/m². Exacerbated by concurrent radiation.
Busulfan, Carmustine, Lomustine	Interstitial pneumonitis, chronic pulmonary fibrosis.	Busulfan cumulative dose >500 mg.
Cytarabine, Methotrexate, Cyclophosphamide	Acute noncardiogenic pulmonary edema.	Occurs within days of administration; causes long-term pulmonary function deficits.
Radiation Therapy	Acute pneumonitis, chronic restrictive lung disease. Impairs alveolar proliferation and type II pneumocyte surfactant production.	Mantle, mediastinal, whole lung, or Total Body Irradiation (TBI >12 Gy fractionated).
Hematopoietic Stem Cell Transplant	Bronchiolitis obliterans syndrome, chronic lung graft-versus-host disease.	Allogeneic transplantation.

Screening And Surveillance

Regular monitoring required for dyspnea on exertion and chronic cough.
Pulmonary function testing consistently demonstrates decreased mean total lung volume and reduced diffusion capacity of carbon monoxide (DLCO) dropping to 60% of predicted values in severely affected survivors.